Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BIIB

Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.

Benzinga

Biogen Stock: Is Wall Street Bullish or Bearish?

Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Benzinga

What to Expect From Biogen’s Q3 2025 Earnings Report

Biogen is slated to release its fiscal third-quarter earnings later this month, and analysts are expecting its earnings to drop in the single-digit range.

Barchart

Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy

On Tuesday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Biogen Inc.’s (NASDAQ: BIIB) supplemental New Drug Application (sNDA) for the high-dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).

Benzinga

Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment

Biogen Inc. (NASDAQ:BIIB) on Thursday agreed to acquire Massachusetts-based Alcyone Therapeutics for $85 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Is Biogen Stock Underperforming the Nasdaq?

Although Biogen has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Biogen Stock: Analyst Estimates & Ratings

Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Barchart

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

Benzinga

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

Benzinga

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Benzinga

Here's What to Expect From Biogen's Next Earnings Report

Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline.

Barchart

Is Biogen Stock Underperforming the S&P 500?

Biogen has significantly underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Do Wall Street Analysts Like Biogen Stock?

Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Earnings Preview: What To Expect From Biogen's Report

Biogen is poised to announce its first-quarter results next month, and analysts predict a single-digit dip in the company’s bottom-line figure.

Barchart

How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects.

Barchart

Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Biogen Stock Is Mutating Into a Value Play

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Barchart

Biogen's Quarterly Earnings Preview: What You Need to Know

Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line.

StockNews.com

3 Biotech Stocks Innovating the Future of Medicine

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing advancements like AI. Therefore, fundamentally sound biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD), which are at the forefront of innovation, could be ideal portfolio additions. Read more.

Barchart

Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Barchart

Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?

Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

StockNews.com

3 Biotech Stocks Predicted to Surge on Medical Innovation

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, investors might consider adding fundamentally strong biotech stocks like Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD) to their portfolio for an impactful investment. Continue reading….

1 2 3 4 5

People

Kritika SarmahHer

727 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.